Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Holders of 5% or more of QCLS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Q/C Technologies, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 13D/A | 74.00%8.48M shares | – | Nov 18, 20251 filing | Nov 18, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
1 Schedule 13D or 13G filing on Q/C Technologies, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 20254:29 PM ET | PharmaCyte Biotech, Inc. | 13D/A | 74.00%8.48M shares | – | Nov 14, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Q/C Technologies, Inc. shares.
No Form 144 notices for Q/C Technologies, Inc. are on file.